Business Description
Xvivo Perfusion AB
ISIN : SE0004840718
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 17.36 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.33 | |||||
Interest Coverage | 1.24 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 24.75 | |||||
Beneish M-Score | -2.25 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 44.8 | |||||
3-Year FCF Growth Rate | -5.1 | |||||
3-Year Book Growth Rate | 20.7 | |||||
Future 3-5Y Total Revenue Growth Rate | 2 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 46.75 | |||||
9-Day RSI | 57.11 | |||||
14-Day RSI | 58.02 | |||||
6-1 Month Momentum % | 28.41 | |||||
12-1 Month Momentum % | 13.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.14 | |||||
Quick Ratio | 5.09 | |||||
Cash Ratio | 4.06 | |||||
Days Inventory | 300.75 | |||||
Days Sales Outstanding | 72.7 | |||||
Days Payable | 89.22 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.1 | |||||
Shareholder Yield % | -0.88 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 74.49 | |||||
Operating Margin % | 0.9 | |||||
Net Margin % | 15.37 | |||||
FCF Margin % | 7.61 | |||||
ROE % | 5.56 | |||||
ROA % | 4.74 | |||||
ROIC % | 0.33 | |||||
ROC (Joel Greenblatt) % | 41.97 | |||||
ROCE % | 5.3 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 102.76 | |||||
Forward PE Ratio | 113.64 | |||||
PE Ratio without NRI | 102.76 | |||||
Shiller PE Ratio | 780.21 | |||||
PS Ratio | 15.86 | |||||
PB Ratio | 5.13 | |||||
Price-to-Tangible-Book | 13.65 | |||||
Price-to-Free-Cash-Flow | 205.52 | |||||
Price-to-Operating-Cash-Flow | 205.52 | |||||
EV-to-EBIT | 98.28 | |||||
EV-to-Forward-EBIT | 183.85 | |||||
EV-to-EBITDA | 98.28 | |||||
EV-to-Forward-EBITDA | 75.62 | |||||
EV-to-Revenue | 15.74 | |||||
EV-to-Forward-Revenue | 12.99 | |||||
EV-to-FCF | 204.27 | |||||
Price-to-Projected-FCF | 5.1 | |||||
Price-to-Median-PS-Value | 0.96 | |||||
Price-to-Graham-Number | 7.87 | |||||
Price-to-Net-Current-Asset-Value | 17.13 | |||||
Price-to-Net-Cash | 33.63 | |||||
Earnings Yield (Greenblatt) % | 1.02 | |||||
FCF Yield % | 0.46 | |||||
Forward Rate of Return (Yacktman) % | 11.04 |